For example, women with hormone-dependent breast cancer treated with aromatase inhibitors have a very high risk of metabolic syndrome, hypertension and visceral obesity, increasing the risk of cardiovascular mortality [122], and cardiometabolic diseases, through direct and indirect pathways, increased the risk of breast cancer recurrence [123]. The gene discussed is CYP19A1; the disease is metabolic syndrome.